Skip to main content
Caplight Logo









Cytochroma

Cytochroma

Private
EdinburghHealthcare & Life Scienceshttps://cytochroma.org/

Last Round

Accelerator

Sep 15, 2025

Total Funding Raised

$1.64M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Cytochroma is a biotechnology company that provides genetically diverse, iPSC-derived cell models and screening services to predict drug safety and efficacy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

iPSCinduced pluripotent stem cellsdrug discoveryorganoidspreclinical safety testingorgan-on-a-chiphigh-throughput screeningwet AIphenotypic screeninganimal-free testingtoxicity predictionhuman tissue modelsin vitro modelsAI drug discoverybiotech services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cytochroma Comparables

Compare Cytochroma with similar companies based on industry and business-model similarity.

Cytochroma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xellar Biosystems
84%
Curi Bio
81%
Hesperos Inc.
79%

Cytochroma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorSep 15, 2025
Early FundingOct 17, 2024
SeedDec 16, 2021

Key People

Founding team and executive leadership

Kate Cameron

Founder CEO, CEO

Founding Team

Cytochroma Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 15, 2025

    $340K round led by Morgan Stanley Inclusive & Sustainable Ventures

  • Oct 17, 2024

    Received investment from Investing Women Angels.

Cytochroma Filings

Explore SEC and related filing metadata, where available.

Cytochroma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cytochroma's valuation, stock price, and market status.

Is Cytochroma a public or private company?

Cytochroma is a private company.

What is the current stock price of Cytochroma?

Cytochroma is a private company with no public stock price. No recent secondary market data is available.

How much is Cytochroma worth (valuation)?

Valuation information for Cytochroma is not publicly available.

Can I buy Cytochroma stock?

Cytochroma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cytochroma's last funding round?

Cytochroma's most recent funding round was Accelerator on September 15, 2025.

Who are the main investors in Cytochroma?

Key investors in Cytochroma include Angel Academe, Morgan Stanley Inclusive & Sustainable Ventures.

Will Cytochroma IPO soon?

No public IPO plans have been announced for Cytochroma.

How can I track Cytochroma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cytochroma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersEdinburgh
Employee Range5
Year Founded2017
Last FundingSep 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?